我的帳戶 | NanoParma

Testing Restarts
Lives Safely

The world has changed. People’s livelihoods and the health of the world may never be “as it was” pre-pandemic.

In these times we all need peace of mind: NanoParma™ provides rapid, easy-to-use, and accurate testing for COVID-19 screening and immune protection.

Let’s go travel, enjoy a meal, attend a game, and work safely again!

NanoParma™ Testing enables individuals to safely and conveniently self-test for COVID-19 immune protection.

Test at a workplace, an event, at home or anywhere! Results can be uploaded to ParmaPass™ where maps of COVID-19 “safe zones” can be found for any community you reside in or need to travel to. Let’s work together to create better health for everyone!

See how NanoParma™ can help restart lives safely.

Testing

Empowers

communities

Choose A Scenario:

1. Travel

2. Business

3. School

4. Medical

WHY

SeraParma™

TESTING

RAPID

Fast and reliable results in only 20 minutes
Early detection and early intervention

ACCURATE

Over 99% of sensitivity and specificity

As accurate as the “Gold Standard" PCR testing

WHY

SeraParma™

TESTING

RAPID

Fast and reliable results in only 20 minutes
Early detection and early intervention

ACCURATE

Greater than 99% sensitivity and specificity
As accurate as “Gold Standard" PCR testing

WHY

SeraParma™

TESTING

RAPID

Fast and reliable results in only 20 minutes
Early detection and early intervention

ACCURATE

Over 99% of sensitivity and specificity
As accurate as the PCR testing

NanoParma™ testing is an easy-to-use, rapid and accurate COVID-19 antibody testing system.

MucoParma™ tests saliva for IgA (infection) while SeraParma™ tests for IgM, IgG and neutralizing antibodies (immunity) using only a single drop of blood.

Types of

NanoParma™ Testing

MucoParma™ COVID-19 IgA

IgA is a primary class of antibodies found in saliva, part of the mucosal membrane system. When someone is infected with SARS-CoV-2, IgA initially rises as early as IgM. By testing saliva IgA, MucoParma™ enables organizations and individuals to rapidly screen for infection with ease and convenience.

SeraParma™ COVID-19 IgM/IgG

IgM is a major class of antibodies produced by the immune system and circulated in the blood once someone is infected with SARS-CoV-2 virus. A positive IgM test indicates the body is currently infected and means the immune system is responding to COVID-19.

IgG is produced in COVID-19 patients within 7-10 days after the occurrence of an infection. IgG normally remains in the blood post-recovery and helps protect a patient from future infections.

Usually, a lateral flow based rapid antibody test is not used for infection diagnoses due to its lack of sensitivity. However, SeraParma™ possesses 1,000 times higher sensitivity than conventional lateral flow technologies. The secret is in the nanoparticle. Data has shown 100% agreement between FDA validated results for PCR testing and those of SeraParma™ testing for COVID-19 IgM/IgG. Furthermore, by testing IgM and IgG simultaneously, we get to know the precise status of a patient’s infection and/or immunity and are able to take the right action to help make communities safer.

SeraParma™ COVID-19 Neutralizing Antibodies

After recovery from COVID-19, IgG may remain in one’s blood circulation but it’s not guaranteed those antibodies are able to defend SARS-CoV-2 in the future. Similarly, after receiving a vaccine shot, it’s not guaranteed the antibodies produced by one’s immune system can defend future COVID-19. It takes specific neutralizing antibodies to defend cells from SARS-CoV-2 infection. Our testing of SeraParma™ COVID-19 Neutralizing Antibodies is to confirm the existence of the neutralizing antibodies that possess immune protection from COVID-19.

MucoParma™ COVID-19 IgA

IgA is a primary class of antibodies found in saliva, part of the mucosal membrane system. When someone is infected with SARS-CoV-2, IgA initially rises as early as IgM. By testing saliva IgA, MucoParma™ enables organizations and individuals to rapidly screen for infection with ease and convenience.

SeraParma™ COVID-19 IgM/IgG

IgM is a major class of antibodies produced by the immune system and circulated in the blood once someone is infected with SARS-CoV-2 virus. A positive IgM test indicates the body is currently infected and means the immune system is responding to COVID-19.

IgG is produced in COVID-19 patients within 7-10 days after the occurrence of an infection. IgG normally remains in the blood post-recovery and helps protect a patient from future infections.

Usually, a lateral flow based rapid antibody test is not used for infection diagnoses due to its lack of sensitivity. However, SeraParma™ possesses 1,000 times higher sensitivity than conventional lateral flow technologies. The secret is in the nanoparticle.

Data has shown 100% agreement between FDA validated results for PCR testing and those of SeraParma™ testing for COVID-19 IgM/IgG. Furthermore, by testing IgM and IgG simultaneously, we get to know the precise status of a patient’s infection and/or immunity and are able to take the right action to help make communities safer.

SeraParma™ COVID-19 Neutralizing Antibodies

After recovery from COVID-19, IgG may remain in one’s blood circulation but it’s not guaranteed those antibodies are able to defend SARS-CoV-2 in the future.

Similarly, after receiving a vaccine shot, it’s not guaranteed the antibodies produced by one’s immune system can defend against future infections.

SeraParma™ tests for specific SARS-CoV-2 Neutralizing Antibodies to confirm the existence of immune protection from COVID-19.

ParmaPass™
Safe Zones

We all want the pandemic to be over. We all hope to get back to normal. But history has taught us that vaccination alone cannot single-handedly control a virus.

To avoid lockdown cycles experienced in 2020, we need to curb the spread of the virus using a three-pronged strategy: 1.Vaccinations, 2.Testing/Isolations, and
3.Safe Zone mapping strategies.

NanoParma™ provides innovative testing tools, and also a safe-zone mapping tool to complement the on-going vaccination efforts throughout the world.

Our open-source ParmaPass™ app generates time-stamped, blockchain verifiable certificates of immune status for anyone who has been tested and shared his/her testing results anonymously. Safety is on the way!

Our Team

Jesse Chih-Wei Lin

CEO

MT(ASCPi), MBA

BS in Medical Technology, National Taiwan University (NTU)

Co-founder of BioInnovation Taiwan

President of NTU MedTech Alumni Association

Co-founder and Senior Venture Builder of BlockSmith Venture Studio

7+ years experience in MedTech startup business consulting

Young Taiwanese for Global Health Forum in Taiwan (2017)

Howard Hong-wei yang

CTO

Professor at the Institute of Medical Science & Technology, National Sun-Yat-Sen University (NSYSU), Taiwan

Distinguished Young Scholar in NSYSU (2019-2022)

NIH Postdoctoral Fellow, Georgia Institute of Technology, USA (2013-
2014)

Outstanding Paper Award, Association of Chemical Sensors in Taiwan
(2017/2019/2020)

Project for Excellent Junior Research Investigators, Ministry of
Science and Technology (2017~2021)

Matthew lee

COO

MBA for Tech Commercialization at the University of Texas

First-place, Texas Venture Lab business plan competition – A Rapid
Diagnostic Test for Sepsis

9+ years as IP Attorney in Houston, TX (Morgan Lewis & Bockius/ Lee &
Naughton/LexNovia)

9+ years Patent Examiner/Agent in USPTO

Co-founder and Senior Venture Builder of BlockSmith Venture Studio

Serial entrepreneur

erik wainwright

CMO

15+ years experience in cross culture communication

7+ years experience as executive life coach and marketing consulting

Co-founder of ASHERS LEAVEN

Founding member of BioInnovation Taiwan

Studied Sociology/ Social Psychology/ Cultural Anthropology at Washington State University

Marketing Group

Claire Hsu
Miya Wu
Anita Hsu
Winnie Chou
EJ Wu

R&D Group

Lancelot Lee
Hans pang
Emily hsu

MucoParma™ SARS-COV-2 IgA

IgA is the primary class of antibodies found in saliva, part of mucosal membrane system. When one is SARS-CoV-2 infected, IgA rises as early as IgM (ref). By testing saliva IgA, MucoParma™ enables individuals and business to screen infection rapidly.

SeraParma™ SARS-COV-2 IgM/IgG

IgM is the major class of antibodies produced by immune system and found in blood circulation when one is SARS-CoV-2 infected. A positive IgM test indicates a current COVID-19 and the immune system is responding it.

IgG is produced in COVID-19 patients within 7-10 days after infection. IgG usually remains in the blood after one recovers from the infection to protect one from future infection.

Usually, a lateral flow based rapid antibody test is not used for infection diagnosis due to its compromised sensitivity. However, SeraParma™ possesses 1,000 times higher sensitivity than the old lateral flow technology. Data showed 100% agreement between results of FDA validated PCR tests and SeraParma™ COVID-19 IgM/IgG. Furthermore, by testing IgM and IgG simultaneously, we get to know the status of one’s infection and take the right action.

SeraParma™ COVID-19 Neutralizing Antibodies

After recovery from COVID-19, IgG may remain in one’s blood circulation but it’s not guaranteed those antibodies are able to defend SARS-CoV-2 in the future. Similarly, after receiving a vaccine shot, it’s not guaranteed the antibodies produced by one’s immune system can defend future COVID-19. It takes specific neutralizing antibodies to defend cells from SARS-CoV-2 infection. Our testing of SeraParma™ COVID-19 Neutralizing Antibodies is to confirm the existence of the neutralizing antibodies that possess immune protection from COVID-19.

See how NanoParma™ can help restart lives safely.

RAPID

EASY-TO-USE

ACCURATE

Over 99% of sensitivity and specificity

As accurate as the “Gold Standard" PCR testing

immune protection

RAPID

EASY-TO-USE

ACCURATE

immune protection

RAPID

EASY-TO-USE

ACCURATE

immune protection

NanoParma™ testing is an easy-to-use, rapid and accurate COVID-19 antibody testing system.

MucoParma™ tests saliva for IgA (infection) while SeraParma™ tests for IgM, IgG and neutralizing antibodies (immunity) using only a single drop of blood.

IgM is a major class of antibodies produced by the immune system and circulated in the blood once someone is infected with SARS-CoV-2 virus. A positive IgM test indicates the body is currently infected and means the immune system is responding to COVID-19.

IgG is produced in COVID-19 patients within 7-10 days after the occurrence of an infection. IgG normally remains in the blood post-recovery and helps protect a patient from future infections.

SeraParma™ COVID-19 Neutralizing Antibodies

IgM is a major class of antibodies produced by the immune system and circulated in the blood once someone is infected with SARS-CoV-2 virus. A positive IgM test indicates the body is currently infected and means the immune system is responding to COVID-19.

IgG is produced in COVID-19 patients within 7-10 days after the occurrence of an infection. IgG normally remains in the blood post-recovery and helps protect a patient from future infections.

SeraParma™ COVID-19 Neutralizing Antibodies

Marketing Group

Claire Hsu
Miya Wu
Anita Hsu
Winnie Chou
EJ Wu

R&D Group

Lancelot Lee
Hans pang
Emily hsu

IgA is the primary class of antibodies found in saliva, part of mucosal membrane system. When one is SARS-CoV-2 infected, IgA rises as early as IgM (ref). By testing saliva IgA, MucoParma™ enables individuals and business to screen infection rapidly.

IgM is the major class of antibodies produced by immune system and found in blood circulation when one is SARS-CoV-2 infected. A positive IgM test indicates a current COVID-19 and the immune system is responding it.

IgG is produced in COVID-19 patients within 7-10 days after infection. IgG usually remains in the blood after one recovers from the infection to protect one from future infection.

SeraParma™ COVID-19 Neutralizing Antibodies

See how NanoParma™ can help restart lives safely.

RAPID

EASY-TO-USE

ACCURATE

Over 99% of sensitivity and specificity

As accurate as the “Gold Standard" PCR testing

immune protection

RAPID

EASY-TO-USE

ACCURATE

immune protection

RAPID

EASY-TO-USE

ACCURATE

immune protection

NanoParma™ testing is an easy-to-use, rapid and accurate COVID-19 antibody testing system. MucoParma™ tests saliva for IgA (infection) while SeraParma™ tests for IgM, IgG and neutralizing antibodies (immunity) using only a single drop of blood.

IgM is a major class of antibodies produced by the immune system and circulated in the blood once someone is infected with SARS-CoV-2 virus. A positive IgM test indicates the body is currently infected and means the immune system is responding to COVID-19.

IgG is produced in COVID-19 patients within 7-10 days after the occurrence of an infection. IgG normally remains in the blood post-recovery and helps protect a patient from future infections.

SeraParma™ COVID-19 Neutralizing Antibodies

IgM is a major class of antibodies produced by the immune system and circulated in the blood once someone is infected with SARS-CoV-2 virus. A positive IgM test indicates the body is currently infected and means the immune system is responding to COVID-19.

IgG is produced in COVID-19 patients within 7-10 days after the occurrence of an infection. IgG normally remains in the blood post-recovery and helps protect a patient from future infections.

SeraParma™ COVID-19 Neutralizing Antibodies

Marketing Group

Claire HsuMiya WuAnita HsuWinnie ChouEJ Wu

R&D Group

Lancelot LeeHans pangEmily hsu

IgA is the primary class of antibodies found in saliva, part of mucosal membrane system. When one is SARS-CoV-2 infected, IgA rises as early as IgM (ref). By testing saliva IgA, MucoParma™ enables individuals and business to screen infection rapidly.

IgM is the major class of antibodies produced by immune system and found in blood circulation when one is SARS-CoV-2 infected. A positive IgM test indicates a current COVID-19 and the immune system is responding it.

IgG is produced in COVID-19 patients within 7-10 days after infection. IgG usually remains in the blood after one recovers from the infection to protect one from future infection.

SeraParma™ COVID-19 Neutralizing Antibodies

NanoParma™ testing is an easy-to-use, rapid and accurate COVID-19 antibody testing system.

MucoParma™ tests saliva for IgA (infection) while SeraParma™ tests for IgM, IgG and neutralizing antibodies (immunity) using only a single drop of blood.

Claire Hsu
Miya Wu
Anita Hsu
Winnie Chou
EJ Wu

Lancelot Lee
Hans pang
Emily hsu